-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes SAB Biotherapeutics at Buy, Announces Price Target of $10

Benzinga·05/14/2025 16:56:58
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar assumes SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $10.